Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.55 |
| ▸ | BRD3 | Q15059 | 4/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | DHODH | Q02127 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | TAS1R3 | Q7RTX0 | 4/20 | 0.46 |
| ▸ | TAS1R1 | Q7RTX1 | 4/20 | 0.46 |
| ▸ | TAS1R2 | Q8TE23 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4148660 | 0.92 | TDP1 (0.54) | CYP2D6KCNH2BRD3MEN1KMT2A | |
| SCHEMBL4022197 | 0.88 | CYP2D6 (0.61) | CYP2D6KCNH2BRD3MEN1KMT2A | |
| SCHEMBL21114855 | 0.88 | CYP2D6 (0.61) | CYP2D6KCNH2BRD3MEN1KMT2A | |
| SCHEMBL29905613 | 0.88 | CYP2D6 (0.61) | CYP2D6KCNH2BRD3MEN1KMT2A | |
| SCHEMBL4021701 | 0.85 | CYP2D6 (0.60) | CYP2D6KCNH2BRD3MEN1KMT2A | |
| SCHEMBL4024942 | 0.85 | CYP2D6 (0.60) | CYP2D6KCNH2BRD3MEN1KMT2A | |
| SCHEMBL4025938 | 0.83 | CYP2D6 (0.67) | CYP2D6KCNH2BRD3MEN1KMT2A | |
| SCHEMBL4021888 | 0.83 | CYP2D6 (0.67) | CYP2D6KCNH2BRD3MEN1KMT2A | |
| SCHEMBL4024141 | 0.83 | CYP2D6 (0.67) | CYP2D6KCNH2BRD3MEN1KMT2A | |
| SCHEMBL4172365 | 0.83 | CYP2D6 (0.60) | CYP2D6KCNH2BRD3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1646610-B1 | TETRAHYDROCARBAZOLE DERIVATIVES AND THEIR PHARMACEUTICAL USE | SMITHKLINE BEECHAM CORP (US) | 2009-07-22 | — | — | EP | claimed |
| US-7419997-B2 | Tetrahydrocarbazole derivatives and their pharmaceutical use | SMITHKLINE BEECHAM CORPORATION (US) | 2008-09-02 | — | — | US | claimed |
| US-20060148857-A1 | Tetrahydrocarbazole derivatives and their pharmaceutical use | SMITHKLINE BEECHAM CORPORATION | 2006-07-06 | — | — | US | claimed |
| EP-1646610-B1 | TETRAHYDROCARBAZOLE DERIVATIVES AND THEIR PHARMACEUTICAL USE | SMITHKLINE BEECHAM CORP (US) | 2009-07-22 | — | — | EP | disclosed |
| EP-1646610-B1 | TETRAHYDROCARBAZOLE DERIVATIVES AND THEIR PHARMACEUTICAL USE | SMITHKLINE BEECHAM CORP (US) | 2009-07-22 | — | — | EP | disclosed |
| US-20090170906-A1 | HCV INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2009-07-02 | — | — | US | disclosed |
| US-20090170906-A1 | HCV INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2009-07-02 | — | — | US | disclosed |
| US-20090170906-A1 | HCV INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2009-07-02 | — | — | US | disclosed |
| US-7419997-B2 | Tetrahydrocarbazole derivatives and their pharmaceutical use | SMITHKLINE BEECHAM CORPORATION (US) | 2008-09-02 | — | — | US | disclosed |
| US-7419997-B2 | Tetrahydrocarbazole derivatives and their pharmaceutical use | SMITHKLINE BEECHAM CORPORATION (US) | 2008-09-02 | — | — | US | disclosed |
| US-7419997-B2 | Tetrahydrocarbazole derivatives and their pharmaceutical use | SMITHKLINE BEECHAM CORPORATION (US) | 2008-09-02 | — | — | US | disclosed |
| US-20060148857-A1 | Tetrahydrocarbazole derivatives and their pharmaceutical use | SMITHKLINE BEECHAM CORPORATION | 2006-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170906-A1 | HCV INHIBITORS | HAVCR2, MAVS, EIF2AK2 | CYP2D6 994/4885KCNH2 4356/4885BRD3 4059/4885 |
| US-20060148857-A1 | Tetrahydrocarbazole derivatives and their pharmaceutical use | HMBS, UGT2B17, TPMT | CYP2D6 660/4885KCNH2 4337/4885BRD3 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.